Salarius Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Jonathan I Lieber, a Director of Salarius Pharmaceuticals, Inc., received 2,000 shares of common stock on August 31, 2026.
Frederick Pierce Ii, Chief Executive Officer of Salarius Pharmaceuticals, Inc., received 33,455 shares of common stock on August 31, 2026.
Peter Klaus Marschel, Chief Business Officer of Salarius Pharmaceuticals, Inc., received 3,900 shares of common stock on August 31, 2026.
Mark J Rosenblum, Chief Financial Officer of Salarius Pharmaceuticals, Inc., received 9,682 shares of common stock on August 31, 2026.
Barbara Louise Hibner, Chief Scientific Officer of Salarius Pharmaceuticals, Inc., received 4,216 shares of common stock on August 31, 2026.
Arnold C Hanish, a Director of Salarius Pharmaceuticals, Inc., received 3,000 shares of common stock on August 31, 2026.
Paul Lammers, a Director of Salarius Pharmaceuticals, Inc., received 2,000 shares of common stock on August 31, 2026.
Tess Burleson, a Director of Salarius Pharmaceuticals, Inc., received 2,000 shares of common stock on August 31, 2026.
William K. Mcvicar, a Director of Salarius Pharmaceuticals, Inc., received 3,000 shares of common stock on August 31, 2026.
Patricia G. Gauthier, a Director of Salarius Pharmaceuticals, Inc., received 2,000 shares of common stock on August 31, 2026.
Salarius Pharmaceuticals Director Arnold C. Hanish sold a total of 27 common shares at $0.6397 per share on December 30, 2025, under a Rule 10b5-1 plan.
Salarius Pharmaceuticals Director Arnold C. Hanish acquired 5,000 shares of common stock at a weighted average price of $0.7481, increasing his indirect beneficial ownership.
Form 4: Salarius CFO Buys 20,000 Shares
Salarius Pharmaceuticals' Executive VP Finance and CFO, Mark J. Rosenblum, purchased 20,000 shares of common stock, signaling confidence in the company.
David J. Arthur, CEO of Salarius Pharmaceuticals, acquired 20,500 stock options on April 11, 2024.